Archives: Agenda
Afternoon refreshments and networking
Lunch and networking
Leveraging the patient perspective: Using the real disease experts to enhance protocol design
- Integrating patient insights early in protocol design to streamline clinical trial processes
- Utilizing patient networks when designing effective protocols to ensure patient centricity
- Reducing the patient burden while enhancing endpoint selection in rare disease trial design
Morning refreshments and networking
Interactive Speaker-Hosted Roundtable Discussions
Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Each discussion will be led by a table moderator and will focus on a different challenge within rare disease clinical trials.
Roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others. After 45 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.
Roundtable 1: Reducing caregiver burden and trial fatigue in rare disease studies
Roundtable 2: Enhancing site relationships to ensure your rare disease clinical trial runs seamlessly
Roundtable 3: Effectively tracking vendors to ensure regulatory compliance and reduce roadblocks
Chairperson’s opening remarks
Registration and refreshments
Accelerating rare disease clinical trials to curb competition and navigate increasing industry pressure
- Tips and tricks on how to shorten development timelines and reach first-in-human studies faster
- Identifying opportunities to compress timelines without compromising quality
- Collaborating with CROs effectively to drive operational efficiency and aid faster study start-up
Accelerating Pediatric Rare-Disease Drug Development: Trial Design, Recruitment, and Regulatory strategy for Early-Life Impact
- Designing development strategies that support earlier intervention and improve long-term outcomes
- Gaining practical insights into how to optimize trial design, patient recruitment, and the use of real-world endpoints
- Addressing the complexities of small, heterogeneous pediatric populations to enhance study feasibility and success
- Engaging regulators effectively and plan for how pediatric medicines are evaluated differently—especially for cell and gene therapies and earlier treatment approaches